Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of RT001 in Amyotrophic Lateral Sclerosis
2020-003962-38Phase 2Completed
- Sponsor
- Retrotope
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing RT001 with Placebo (2 arms). Primary endpoint: Change in ALSFRS-R. Started Nov 2020; status: completed.
02
Drugs
RT001
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2020-003962-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003962-38.